Cargando…

Classification of chronic cough by systematic treatment cascade trial starting with beta agonist

BACKGROUND: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interest...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Hideyasu, Hayashi, Masamichi, Saito, Yuji, Mieno, Yuki, Takeuchi, Yasuo, Sasaki, Fumihiko, Sakakibara, Hiroki, Naito, Kensei, Okazawa, Mitsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602065/
https://www.ncbi.nlm.nih.gov/pubmed/23391257
http://dx.doi.org/10.1186/1745-9974-9-4
_version_ 1782263528625799168
author Shimizu, Hideyasu
Hayashi, Masamichi
Saito, Yuji
Mieno, Yuki
Takeuchi, Yasuo
Sasaki, Fumihiko
Sakakibara, Hiroki
Naito, Kensei
Okazawa, Mitsushi
author_facet Shimizu, Hideyasu
Hayashi, Masamichi
Saito, Yuji
Mieno, Yuki
Takeuchi, Yasuo
Sasaki, Fumihiko
Sakakibara, Hiroki
Naito, Kensei
Okazawa, Mitsushi
author_sort Shimizu, Hideyasu
collection PubMed
description BACKGROUND: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators. OBJECTIVES: The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the β(2) agonist and second to sub-categorize β(2) agonist responsive cough (BRC) by the airway hyperresponsiveness. METHODS: One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made. RESULTS: One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study. CONCLUSIONS: The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan. TRIAL REGISTRATION: University hospital medical information network (UMIN 000007483)
format Online
Article
Text
id pubmed-3602065
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36020652013-03-20 Classification of chronic cough by systematic treatment cascade trial starting with beta agonist Shimizu, Hideyasu Hayashi, Masamichi Saito, Yuji Mieno, Yuki Takeuchi, Yasuo Sasaki, Fumihiko Sakakibara, Hiroki Naito, Kensei Okazawa, Mitsushi Cough Research BACKGROUND: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators. OBJECTIVES: The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the β(2) agonist and second to sub-categorize β(2) agonist responsive cough (BRC) by the airway hyperresponsiveness. METHODS: One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made. RESULTS: One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study. CONCLUSIONS: The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan. TRIAL REGISTRATION: University hospital medical information network (UMIN 000007483) BioMed Central 2013-02-07 /pmc/articles/PMC3602065/ /pubmed/23391257 http://dx.doi.org/10.1186/1745-9974-9-4 Text en Copyright ©2013 Shimizu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Shimizu, Hideyasu
Hayashi, Masamichi
Saito, Yuji
Mieno, Yuki
Takeuchi, Yasuo
Sasaki, Fumihiko
Sakakibara, Hiroki
Naito, Kensei
Okazawa, Mitsushi
Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
title Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
title_full Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
title_fullStr Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
title_full_unstemmed Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
title_short Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
title_sort classification of chronic cough by systematic treatment cascade trial starting with beta agonist
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602065/
https://www.ncbi.nlm.nih.gov/pubmed/23391257
http://dx.doi.org/10.1186/1745-9974-9-4
work_keys_str_mv AT shimizuhideyasu classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT hayashimasamichi classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT saitoyuji classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT mienoyuki classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT takeuchiyasuo classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT sasakifumihiko classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT sakakibarahiroki classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT naitokensei classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist
AT okazawamitsushi classificationofchroniccoughbysystematictreatmentcascadetrialstartingwithbetaagonist